(ii) MOLECULE TYPE: synthetic DNA

(iii) SEQUENCE: SEQ ID NO:2

TTGCCGTACC TGACTTAGCC

What is claimed is:

1. A pharmaceutical composition for the therapy and prophylaxis of NF-κB-associated disease which comprises an NF-κB decoy.

2. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.

3. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is an ischemic disease.

4. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.

5. The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic heart disease, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA

20

restenosis.

6.   The pharmaceutical composition according to Claim 1 wherein the NF-κB-associated disease is a cancer metastasis or ~~invasion or cachexia.~~

𝐵

7.   A nucleic acid having a nucleotide sequence corresponding to the 8th through 17th nucleotides from the 5' end of the sequence represented by SEQ ID NO:1 in Sequence Listing or a variant thereof.

8.   The pharmaceutical composition according to Claim 1

𝐵 wherein the ~~NF-κB decoy~~ *nucleotide* is the nucleic acid defined in Claim 7.

𝐵 9.   A liposomal composition comprising the ~~NF-κB decoy~~ *nucleic acid of* defined in Claim 7.

Sub 𝐵² ⟩ 10.   A method for the therapy and prophylaxis of NF-κB-associated disease which comprises administering an effective amount of an NF-κB decoy to a mammal.

Sub 𝐵² ⟩ 11.   The method according to Claim 10 wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.

3.
12.   The method according to Claim 10 wherein the NF-

κB-associated disease is an ischemic disease.

13. The method according to Claim 10 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.

14. The method according to Claim 10 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic heart diseases, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA restenosis.

15. The method according to Claim 10 wherein the NF-κB-associated disease is a cancer metastasis or invasion or cachexia.

16. The method according to Claim 10 wherein the NF-κB decoy is the nucleic acid defined in Claim 7.

17. Use of an NF-κB decoy for the therapy and prophylaxis of NF-κB-associated disease.

18. The use according to Claim 17 wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.

19. The use according to Claim 17 wherein the NF-κB-

associated disease is an ischemic disease.

20. The use according to Claim 17 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.

21. The use according to Claim 17 wherein the NF-κB-associated disease is a reperfusion disorder in ischemic heart diseases, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA restenosis.

22. The use according to Claim 17 wherein the NF-κB-associated disease is a cancer metastasis or invasion or cachexia.

23. The use according to Claim 17 wherein the NF-κB decoy is the nucleic acid defined in Claim 7.